Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | PF-06939999 |
Synonyms | |
Therapy Description |
PF-06939999 is an inhibitor that blocks PRMT5 methyltransferase activity, resulting in decreased histone H2A, H3, and H4 arginine mono- and di-methylation, which potentially leads to modulation of gene expression resulting in decreased tumor cell growth (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PF-06939999 | PF06939999|PF 06939999 | PRMT5 Inhibitor 16 | PF-06939999 is an inhibitor that blocks PRMT5 methyltransferase activity, resulting in decreased histone H2A, H3, and H4 arginine mono- and di-methylation, which potentially leads to modulation of gene expression resulting in decreased tumor cell growth (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03854227 | Phase I | PF-06939999 | A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors | Terminated | USA | 0 |